rs9561778

plus

Geno	Mag	Summary
(G;G)	1	Normal risk of adverse drug reactions from cyclophosphamide treatments
(G;T)	1.5	~2x increased risk of adverse drug reactions from cyclophosphamide treatments
(T;T)	1.5	~2x increased risk of adverse drug reactions from cyclophosphamide treatments

Reference

GRCh38 38.1/141

Chromosome

13

Position

95061461

Gene

ABCC4

is a	snp
is	mentioned by
dbSNP	rs9561778
dbSNP (classic)	rs9561778
ClinGen	rs9561778
ebi	rs9561778
HLI	rs9561778
Exac	rs9561778
Gnomad	rs9561778
Varsome	rs9561778
LitVar	rs9561778
Map	rs9561778
PheGenI	rs9561778
Biobank	rs9561778
1000 genomes	rs9561778
hgdp	rs9561778
ensembl	rs9561778
geneview	rs9561778
scholar	rs9561778
google	rs9561778
pharmgkb	rs9561778
gwascentral	rs9561778
openSNP	rs9561778
23andMe	rs9561778
SNPshot	rs9561778
SNPdbe	rs9561778
MSV3d	rs9561778
GWAS Ctlg	rs9561778

GMAF

0.1837

Max Magnitude

1.5

?

(G;G) (G;T) (T;T)

28

rs9561778 is a SNP in the ATP-binding cassette, sub-family C (CFTR/MRP), member 4 ABCC4 gene.

A stepwise case-control study of ~400 breast cancer Japanese patients receiving cyclophosphamide-based combination chemotherapy, roughly divided equally between those having or not having serious adverse drug reactions (ADRs), concluded that carriers of rs9561778(T) allele had a ~2x higher risk of ADRs. The ADRs for these patients tended to be gastrointestinal toxicity and leukopenia/neutropenia.[PMID 19696793]

[PMID 25677905] Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients